Journal of Diabetology (Jan 2021)

Teneligliptin-induced polyarthritis: A case report

  • Prabhat Kumar Agrawal,
  • Nikhil Pursnani,
  • Ashish Gautam,
  • Boentika Singh,
  • Asvini Yadav

DOI
https://doi.org/10.4103/jod.jod_23_21
Journal volume & issue
Vol. 12, no. 4
pp. 528 – 529

Abstract

Read online

Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects. Patient Concern: We report a case of teneligliptin-induced polyarthritis. Diagnosis: The diagnosis is teneligliptin-induced seronegative, non-erosive, polyarthritis. Intervention: We stopped teneligliptin. Outcome: On stopping teneligliptin, arthralgia was relieved. Lesson: Acute joint pain (arthralgia)/arthritis can be an adverse effect of teneligliptin or DPP-4 inhibitors. Arthritis, as an adverse effect of teneligliptin, is first such case report to the best of our knowledge.

Keywords